Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.sciaf.2021.e00802 http://scihub22266oqcxt.onion/10.1016/j.sciaf.2021.e00802 34095639!8164732!34095639     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Afr 2021 ; 12 (ä): e00802 Nephropedia Template TP {{tp|p=34095639|t=2021. Serologic response to SARS-CoV-2 in an African population |pdf=|usr=}}{{34095639}} gab.com Text Serologic response to SARS-CoV-2 in an African population JO: Sci Afr http://www.kidney.de/pget.php?&tw=1&pmid=34095639 #FOAvip Official case counts suggest Africa has not seen the expected burden of COVID-19 as predicted by international health agencies, and the proportion of asymptomatic patients, disease severity, and mortality burden differ significantly in Africa from what has been observed elsewhere. Testing for SARS-CoV-2 was extremely limited early in the pandemic and likely led to under-reporting of cases leaving important gaps in our understanding of transmission and disease characteristics in the African context. SARS-CoV-2 antibody prevalence and serologic response data could help quantify the burden of COVID-19 disease in Africa to address this knowledge gap and guide future outbreak response, adapted to the local context. However, such data are widely lacking in Africa. We conducted a cross-sectional seroprevalence survey among 1,192 individuals seeking COVID-19 screening and testing in central Cameroon using the Innovita antibody-based rapid diagnostic. Overall immunoglobulin prevalence was 32%, IgM prevalence was 20%, and IgG prevalence was 24%. IgM positivity gradually increased, peaking around symptom day 20. IgG positivity was similar, gradually increasing over the first 10 days of symptoms, then increasing rapidly to 30 days and beyond. These findings highlight the importance of diagnostic testing and asymptomatic SARS-CoV-2 transmission in Cameroon, which likely resulted in artificially low case counts. Rapid antibody tests are a useful diagnostic modality for seroprevalence surveys and infection diagnosis starting 5-7 days after symptom onset. These results represent the first step towards better understanding the SARS-CoV-2 immunological response in African populations. Twit Text FOAVip Serologic response to SARS-CoV-2 in an African population ????Sci Afr http://www.kidney.de/pget.php?&tw=1&pmid=34095639 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34095639 #FOAvip English Wikipedia <ref>{{Cite pmid|34095639}}</ref> Serologic response to SARS-CoV-2 in an African population #MMPMID34095639 Fai KN; Corine TM; Bebell LM; Mboringong AB; Nguimbis EBPT; Nsaibirni R; Mbarga NF; Eteki L; Nikolay B; Essomba RG; Ndifon M; Ntone R; Hamadou A; Matchim L; Tchiasso D; Abah Abah AS; Essaka R; Peppa S; Crescence F; Ouamba JP; Koku MT; Mandeng N; Fanne M; Eyangoh S; Mballa GAE; Esso L; Epee E; Njouom R; Okomo Assoumou MC; Boum Y Sci Afr 2021[Jul]; 12 (ä): e00802 PMID34095639show ga Official case counts suggest Africa has not seen the expected burden of COVID-19 as predicted by international health agencies, and the proportion of asymptomatic patients, disease severity, and mortality burden differ significantly in Africa from what has been observed elsewhere. Testing for SARS-CoV-2 was extremely limited early in the pandemic and likely led to under-reporting of cases leaving important gaps in our understanding of transmission and disease characteristics in the African context. SARS-CoV-2 antibody prevalence and serologic response data could help quantify the burden of COVID-19 disease in Africa to address this knowledge gap and guide future outbreak response, adapted to the local context. However, such data are widely lacking in Africa. We conducted a cross-sectional seroprevalence survey among 1,192 individuals seeking COVID-19 screening and testing in central Cameroon using the Innovita antibody-based rapid diagnostic. Overall immunoglobulin prevalence was 32%, IgM prevalence was 20%, and IgG prevalence was 24%. IgM positivity gradually increased, peaking around symptom day 20. IgG positivity was similar, gradually increasing over the first 10 days of symptoms, then increasing rapidly to 30 days and beyond. These findings highlight the importance of diagnostic testing and asymptomatic SARS-CoV-2 transmission in Cameroon, which likely resulted in artificially low case counts. Rapid antibody tests are a useful diagnostic modality for seroprevalence surveys and infection diagnosis starting 5-7 days after symptom onset. These results represent the first step towards better understanding the SARS-CoV-2 immunological response in African populations. äSerologic response to SARS-CoV-2 in an African population (epmc).pdf DeepDyve Pubget Overpricing